EPCAM and prostate carcinoma: Consistent with the Atlas of Circulating Rare Cells (69), sequencing of CTC clusters and individual circulating cancer cells revealed the mixed epithelial-mesenchymal markers in hepatocellular carcinoma (Vimentin, epithelial: CDH1, EPCAM, ASGR2, Keratin 8, stemness: CD133, POU5F1, NOTCH1 and STAT3) (62) prostate cancer (EPCAM, keratins, E-cad, Vimentin, CD44) (77) and Vimentin in lung cancer (78).